Form 4: Insmed Executive Receives Stock Options and Restricted Stock Units

S. Nicole Schaeffer, Chief People Strategy Officer at Insmed, acquired stock options and restricted stock units (RSUs) on May 15, 2025.

Summary

• On May 15, 2025, S. Nicole Schaeffer, Chief People Strategy Officer of Insmed Inc., was granted 27,100 stock options with an exercise price of $67.22, expiring on May 15, 2035.
• Schaeffer also acquired 5,578 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock.
• The RSUs vest 25% on the first day of the first month following the first anniversary of the grant date, and 25% on each anniversary thereafter until fully vested.
• The stock options vest 25% on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.
• Following these transactions, Schaeffer directly owns 120,221 shares of Insmed Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize long-term performance and retention.

Industry Context

Stock options and RSUs are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded biotechnology and pharmaceutical companies like Insmed.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning executive interests with company performance.
• Employees may see the grants as a sign of company growth and stability.

Key Dates

Keywords

Insmed, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, Executive Compensation, S. Nicole Schaeffer